Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PREGnant)
What is the purpose of this trial?
A Phase 3 randomized clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to placebo.
- Ages18 years - 38 years
- GenderFemale only
- Trial withYale University School of Medicine
- Start Date12/01/2021
- End Date10/31/2023
- Last Updated01/28/2022
- Study HIC#2000027121